report_lead_image_with_gradient.png
Q1 2025

Healthtech Public Comp Sheet and Valuation Guide

Download this Report
To download this report, please complete the form below

Fill out the form to download a preview of this report. The full report is available through the PitchBook Platform.
23andMe bankruptcy caps difficult quarter for healthtech

The healthtech sector weathered significant challenges in Q1, with most public companies experiencing share price declines mirroring broader market losses. The virtual care and remote patient monitoring segment was particularly hard hit, although benefit management companies such as Claritev and Progyny bucked the trend with gains of 58% and 26%, respectively. The Trump administration’s tariff announcements have created market volatility, potentially delaying anticipated IPOs such as Hinge Health and further straining the sector’s already limited liquidity options.

Q1 also saw major structural changes with two significant take-private transactions: Transcarent’s acquisition of Accolade at a $621 million valuation and Nexus’s $1.3 billion sale to TA Associates Management. And perhaps most notably, former industry darling 23andMe was delisted from Nasdaq after filing for bankruptcy, marking a dramatic fall from its $6 billion SPAC valuation in 2021.

Our Q1 2025 Healthtech Public Comp Sheet and Valuation Guide tracks metrics for key publicly traded companies that include stock performance, changes in valuation, historical valuations, revenue growth, EBITDA growth, and EBITDA margins. It is constructed using the PitchBook Excel plugin available to subscribers.


Table of contents
Key takeaways 2
Stock returns 4
Valuations 5
Revenue 6
EBITDA 8